Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Fishbolb (65.45) Submitted: 10/16/2012 6:42:19 PM : Start Price: $10.78 ACHN Score: +43.24

Late to the Hep C game.

getrichslowfool (< 20) Submitted: 1/13/2012 3:21:38 PM : Start Price: $12.32 ACHN Score: -67.22

Yeah it's run up a bunch recently, but I think IDIX will get bought out and this will run up more with it. Time will tell

portefeuille (99.74) Submitted: 12/15/2011 9:16:46 PM : Start Price: $4.80 ACHN Score: +36.20

There are currently 2600 ACHN shares in my "fund" with break-even of around 3.73 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

jamescraigjones (< 20) Submitted: 10/19/2011 10:43:10 AM : Start Price: $6.22 ACHN Score: -12.04

It is clear to see that the Hep C market will be exploding in the next year to 3 years as developers continue to improve on the technology and pipelines. Regardless of how the sector or the overall market is performing, you cant ignore the kind of money that this market will tap into.

EclecticRecluse (77.81) Submitted: 5/25/2011 10:01:35 AM : Start Price: $5.87 ACHN Score: -4.98

Low Sales and Return on Equity

THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:24:28 AM : Start Price: $5.99 ACHN Score: +5.83

Shorting a bunch of biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

poorbastard2011 (< 20) Submitted: 1/14/2011 7:04:28 AM : Start Price: $5.04 ACHN Score: +22.69

Long Term Bullish Breakout
Short Term Upward Sloping Trading Channel
Short Term Bullish Breakout

zzlangerhans (99.78) Submitted: 12/14/2010 11:27:26 AM : Start Price: $3.06 ACHN Score: -118.42

Achillion survived a 50M dilutive financing in August to rise significantly after the initiation of the phase II trial of ACH-1625. These events mean that Achillion will end the year with a comfortable cash cushion but also a bloated market cap which is now disproportionate to their risk/benefit ratio. I doubt 28 day data on ACH-1625 will be remarkable enough to lift the share price in early 2011, leaving the rest of 2011 before 12 week data provides a more substantial catalyst. In the meantime, the stock will remain exquisitely vulnerable to broad market pullbacks. In addition, the most recent PR fails to mention elvucitabine, which makes me wonder if this compound is simply pipeline window dressing.

NetscribePhrmtcl (96.24) Submitted: 3/20/2007 8:42:53 AM : Start Price: $7.06 ACHN Score: +11.92

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals and antibacterials. It is targeting the antiviral development efforts on treatments for HIV infection and chronic hepatitis C, and is directing its antibacterial development efforts toward treatments for serious hospital-based bacterial infections.

Its two lead drug candidates are Elvucitabine, which is in the Phase II clinical trials in HIV-infected patients, and ACH-806, which the company is evaluating in collaboration with Gilead Sciences in a Phase I clinical trial for the treatment of chronic hepatitis C. The company is also evaluating its third drug candidate, ACH-702, in late-stage, pre-clinical studies for the treatment of serious hospital-based bacterial infections.

Revenues witnessed a sharp 91% decline for the quarter ended September 2006. The decrease in 2006 is the result of a reduction in milestone payments under collaboration with Gilead Sciences. Net loss applicable to common shareholders increased 71%, reflecting a sharp increase in R&D expenses and administrative costs. The company has incurred losses of $100 million from inception to September 2006 and had an accumulated deficit of $113.6 million through September 30, 2006.

Achillion appears to be a weak investment proposition based on the delay in the expected development timeline for the HIV & HCV program. The launch of a replicase inhibitor for HCV is expected to be in 2011, rather than 2010, which would hamper the company’s near term earning prospects.